Cargando…

The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells

SIMPLE SUMMARY: Patients diagnosed with isocitrate dehydrogenase (IDH)-mutated brain tumors frequently suffer from seizures, and the seizures were shown to promote tumor growth. Anti-seizure medications (antiepileptic drugs) might be able to break this vicious circle. However, it is not yet known wh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dao Trong, Philip, Jungwirth, Gerhard, Unterberg, Andreas, Herold-Mende, Christel, Warta, Rolf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136933/ https://www.ncbi.nlm.nih.gov/pubmed/37190109 http://dx.doi.org/10.3390/cells12081200

Ejemplares similares

Large-Scale Drug Screening in Patient-Derived IDH(mut) Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents
por: Dao Trong, Philip, et al.
Publicado: (2020)

Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
por: Dao Trong, Philip, et al.
Publicado: (2018)

Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort
por: Dao Trong, P., et al.
Publicado: (2023)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
por: Jungwirth, Gerhard, et al.
Publicado: (2019)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
por: Gallus, Marco, et al.
Publicado: (2023)

Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo
por: Yu, Tao, et al.
Publicado: (2021)

Vorasidenib: A promising therapeutic breakthrough for diffuse isocitrate dehydrogenase mutant gliomas
por: Wahid, Abdul, et al.
Publicado: (2023)

Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score
por: Dao Trong, Philip, et al.
Publicado: (2023)

Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma
por: Jungk, Christine, et al.
Publicado: (2019)

Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas
por: Kim, Ja Eun, et al.
Publicado: (2015)

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas
por: Beyer, Sasha J., et al.
Publicado: (2018)

Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
por: Lam, Keng, et al.
Publicado: (2022)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
por: Chang, Chi-Ming, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Organerhalt: Entscheidungskriterien für Patienten mit T3-Larynxkarzinom
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Larynxorganerhalt bis zum T4‑Larynxkarzinom?
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

Human Leucocyte Antigens as Prognostic Markers in Head and Neck Squamous Cell Carcinoma
por: Dyckhoff, Gerhard, et al.
Publicado: (2022)

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma
por: Glowacka, Wioletta K., et al.
Publicado: (2018)

Combined Treatment With Radiotherapy and Immunotherapy for Isocitrate Dehydrogenase Mutant Brainstem Glioma in Adult: A Case Report
por: Morimoto, Takayuki, et al.
Publicado: (2022)

Erratum to: Prognostic value of O(6)-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas
Publicado: (2022)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma
por: Taher, Mohiuddin M., et al.
Publicado: (2020)

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma
por: Yan, Dongming, et al.
Publicado: (2022)

Could Primary Chemoradiotherapy in T2 Glottic Cancers Yield Results Comparable to Primary Radiotherapy in T1? Considerations from 531 German Early Stage Patients
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

Chemoradiotherapy but Not Radiotherapy Alone for Larynx Preservation in T3. Considerations from a German Observational Cohort Study
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

An Observational Cohort Study on 194 Supraglottic Cancer Patients: Implications for Laser Surgery and Adjuvant Treatment
por: Dyckhoff, Gerhard, et al.
Publicado: (2021)

Effect of Penetration Enhancers on Transdermal Delivery of Oxcarbazepine, an Antiepileptic Drug Using Microemulsions
por: Virani, Amitkumar, et al.
Publicado: (2023)

Deep learning super-resolution magnetic resonance spectroscopic imaging of brain metabolism and mutant isocitrate dehydrogenase glioma
por: Li, Xianqi, et al.
Publicado: (2022)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development
por: Huang, Juan, et al.
Publicado: (2019)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
por: Sharma, Nikhil, et al.
Publicado: (2023)

Identification of a New Selective Chemical Inhibitor of Mutant Isocitrate Dehydrogenase-1
por: Kim, Hyo-Joon, et al.
Publicado: (2015)

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
por: Hassan, Usman, et al.
Publicado: (2023)

Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma
por: Lu, Victor M, et al.
Publicado: (2018)

Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients
por: Auezova, Raushan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_875sdbtsl1i9d9j3jau7rj4d70